Read Carlito Lebrilla's Blog Post on "Glycans and Cancer"

InterVenn Blog

Back to blog list
December 12, 2018
InterVenn BioSciences Raises $9.4 Million to Help Physicians Detect Early Ovarian Cancer With a Minimally Invasive Test
By Aldo Carrascoso

Funding to accelerate InterVenn’s development of its AI-driven mass spectrometry platform that measures glycoproteomic markers that have been strongly linked to tumor development and progression.

Redwood City, Calif, December 12, 2018: — InterVenn BioSciences, a life sciences and technology company developing an AI-driven mass spectrometry platform, announced today an institutional investment of $9.4 million led by seasoned biotech investor Genoa Ventures, with participation from True Ventures, Amplify Partners, Boost VC, and Prado SV. The financing will be used to develop the company’s first product, a blood-based ovarian cancer diagnostic. Jenny Rooke, Ph.D., founder and managing director at Genoa Ventures, and Adam D’Augelli, partner at True Ventures, will join InterVenn’s board of directors. Sunil Dhaliwal, general partner at Amplify Partners, will join as a board observer.

Glycoproteomics, an emerging field combining proteomics and glycomics, can help with better biomarker and target discovery, but produces an enormous amount of data in minutes that historically takes months to fully analyze and is often difficult to reproduce. By leveraging mass spectrometry, high resolution characterization of post-translational modifications, and artificial intelligence, InterVenn streamlines and expedites this process and ensures that any variability in the workflow–from the sample collection, processing, and all the way to instrument ingestion — is minimized and the results are reproducible. The company’s first product is a blood-based ovarian cancer diagnostic that is currently undergoing analytical and clinical validation. Once the validation and regulatory processes are completed, the company will begin offering a laboratory diagnostic test.

“Today, the early diagnosis of ovarian cancer is extremely poor, despite its role in significantly improving survival rates,” said Aldo Carrascoso, CEO of InterVenn BioSciences. “We’ve established a talented team of experts in AI, computational biology, mass spectrometry, software engineering, glycoproteomics, and product development who are dedicated to equipping physicians with a reliable, high-performing and cost-effective tool to change the narrative around ovarian cancer. ”

“InterVenn Biosciences has assembled a world-class team that is developing a first of its kind platform aimed at rapidly and accurately harnessing the power of the glycoproteome for disease characterization and drug development,” said Dr. Jenny Rooke. “We believe that the company’s ovarian cancer test is the first of many applications of InterVenn’s powerful platform. Genoa Ventures is thrilled to support InterVenn for the journey ahead.”

Hey! Just letting you know we use cookies. We use cookies to improve your browsing experience. By continuing to browse this site, you agree to our privacy policy and use of cookies.